Globes, Israel’s business newspaper, is reporting that Notal Vision out of Tel Aviv has received FDA approval for the firm’s ForeseeHome age-related macular degeneration (AMD) analysis device. 
Designed to be used by patients at home, the device can help monitor AMD for signs of an oncoming choroidal neovascularization (CNV). It’s not clear what is the functional mechanism of the device, but ForeseeHome will require a prescription and an ophthalmologist to review the results.
Published features from the product page:
Automated, easy to use test – specifically designed for elderly people. Home use – familiar environment reduces anxiety and increases test frequency. Personalized test customized to specific user – higher sensitivity. Automatic analysis – immediate alert (if needed). Controlled environment – accurate results. Data export – off line, in-dept analysis capabilities.
More from Globes [online]: Notal Vision gets FDA nod for AMD home diagnostic kit…
Product page: ForeseeHome…
Product design info…